Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14701 - 14725 of 14743 in total
AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.
Investigational
3-Methyl-5-(7-{4-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]phenoxy}heptyl)-1,2-oxazole is a solid. This compound belongs to the phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring. 3-Methyl-5-(7-{4-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]phenoxy}heptyl)-1,2-oxazole is known to target genome polyprotein.
Experimental
Matched Description: … These are aromatic compounds containing an ether group substituted with a benzene ring. 3-Methyl-5-(7 …
Cannabinol (CBN) is a physiologically inactive constituent of Cannabis sativa.
Experimental
Investigational
Matched Categories: … Cannabinoids and similars …
Carphenazine is an antipsychotic drug, used in hospitalized patients in the management of chronic schizophrenic psychoses.
Withdrawn
AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. It is being pursued by Access Pharmaceuticals, Inc.
Investigational
Experimental
Rimtuzalcap is a novel modulator of small-conductance calcium-activated potassium channels that is under investigation for the treatment of essential tremor.
Investigational
Pipequaline is an anticonflict & anticonvulsant quinoline derivative. It is an anxiolytic drug that was never marketed. It presents a unique chemical structure that does not follow the structural properties of other drugs of its class. Pipequaline has a similar pharmacological profile to the reported for the benzodiazepines. However, it...
Experimental
Matched Description: … However, it presents a significant set of anxiolytic properties with a very little sedative, amnestic …
ATX-101 (medical), sodium deoxycholate for subcutaneous injection, is being evaluated as a treatment for the reduction of localized fat deposits. This includes treatment of superficial lipomas (benign tumors of soft tissue composed of mature fat cells), fat deposits in the submental region of the face/neck, and localized fat deposits in...
Investigational
Matched Description: … of soft tissue composed of mature fat cells), fat deposits in the submental region of the face/neck, and
Tanaproget (NSP-989) is an investigational non-steroidal progestin. It is a high affinity, high efficacy agonist of the progesterone receptor (PR) with a much more selective binding profile relative to most conventional progestins. Because of this tanaproget may prove to produce fewer side effects in comparison. It is currently in the...
Investigational
Matched Description: … It is a high affinity, high efficacy agonist of the progesterone receptor (PR) with a much more selective …
An IgG1 murine monoclonal anti-idiotype antibody (Ab2), ACA-125, was developed to bind to anti-CA 125 antibodies. ACA-125 mimics the tumor-associated antigen CA-125, which can be detected in about 80% of ovarian carcinomas. This new concept of oncological immunotherapy consists of an attempt to trigger the immune system of the host...
Investigational
Matched Description: … To create ACA-125, a hybridoma cell was adapted to serum-free medium and antibody was produced in a hollow …
PRLX 93936 is selectively toxic to cancer cells.
Investigational
MB07133 is a HepDirect prodrug of an activated form of cytarabine (araC), an anti-cancer drug that is used to treat leukemia but is ineffective against primary liver cancer. AraC's anti-cancer activity is associated with its ability to be converted to its biologically active form, araCTP. However, araC is only slowly...
Investigational
Matched Description: … AraC's anti-cancer activity is associated with its ability to be converted to its biologically active …
105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in metastatic colorectal cancer patients. 105AD7 may be a suitable vaccine for treatment of this disease.
Investigational
Investigational
Cambinol is a beta-naphtol derivative that inhibits NAD-dependant deacetylases to reduce cell survival under stress. This activity is currently being investigated for its use as a cancer treatment.
Experimental
REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.
Investigational
PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.
Investigational
Sarconeos is an activator of the MAS receptor.
Investigational
Investigational
R1204 is G-protein-coupled receptor modulator. It is developed for the treatment of depression.
Investigational
Displaying drugs 14701 - 14725 of 14743 in total